Neuren Media and Analyst Coverage, page-1294

Sorry my own text got cutoff from the ridiculously long investment memo in my previous post (always happens).

I posted the update on NTI not to cross-promote (I don’t hold) but because NEU is mentioned and I like to keep abreast of the ‘competition’.What I found most interesting was that NTI appears to be adopting a strategy of chasing both Orphan Drugs (Rett Syndrome and other conditions) and Autism, more broadly, at the same time.I thought this was very timely given the interesting discussion on the other thread sparked by Sillazze’s welcome return to the forum.

Whilst the NTI article is possibly/likely paid promotion and I have my own thoughts about their Ph 2 results in Retts, it was interesting to compare and contrast their development strategy with NEU’s.